Patent analysis on technology development of anti-CD47 antibody and peptide anti-tumor drugsDAI Yue-han, YANG Lin-lin, JIN Chun-peng, L(U) Xiao-meng2305-2311
Promoting patient involvement in medicine R&D in European Union and its implications for ChinaJIANG Yu-xia, MAO Ning-ying2312-2318
Narrowing optional intervention range by pharmacoeconomic evaluation without thresholdGAO Yong-bo, XIAO Yao, SUN Li-hua2319-2322
The enlightenment of german clinical benefit evaluation on the clinical value evaluation of medical insurance access for innovative medicines in ChinaZHAO Hua-ting, YAN Jian-zhou, SHAO Rong2323-2326
Data analysis on new molecular entities approved by FDA in 2018ZHANG Hua-ji, WANG Lei, ZHU Feng-chang, SUN Xiao-can, LIANG Yi, LIU Chang-lei, WANG Ai-guo, DING Li-xia2327-2331
Case studies of salt selection and optimization in drug developmentYE Xuan, ZHANG Min, WANG Qing-li2332-2335
Risk-based C-QTc research strategy in drug cardiac safety evaluationWEN Ke, WANG Jin, CHAI Dong, GONG Jian, TONG Yong-liang, WANG Rui2336-2340
Matrix-assisted laser desorption ionization mass spectrometry imaging and its application in new drug research and developmentLIN Ming, ZHAO Xin, SUN Yi, PU Xiao-ping2341-2346
Prediction of the difference in dissolution behavior of domestic oral oxacillin sodium and process rationality by physiological pharmacokinetic model combined with in vitro similarity dissolution testZHANG Dou-sheng, WANG Chen, YAO Shang-chen, HU Chang-qin, ZHANG Jing-pu2347-2352
Prediction and evaluation of the toxicity of impurities in cephalosporinsHAN Ying, CHEN Bo, LIU Ying, ZHENG Yang-min, ZHANG Xia, YAO Shang-chen, ZHANG Jing-pu, HU Chang-qin2353-2359